WB, IP, IHC-P, IF-IC
H
Endogenous
70-90,120-175
Rabbit IgG
#Q9H3R2
56667
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
| Immunohistochemistry (Paraffin) | 1:50 |
| Immunofluorescence (Immunocytochemistry) | 1:800 - 1:3200 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human MUC13 protein.
Background
Mucin proteins are glycoproteins known for providing protection and lubrication to the luminal epithelial tissues under normal physiologic conditions (1,2). There are three types of mucins based on their structure and location: transmembrane, secreted, and soluble. Mucins can function as oncogenes and exert the effect of tumor-promoting and/or tumor-suppressing factors (3). MUC13 (Mucin13) is a transmembrane mucin. The protein is expressed in the epithelium layer of large intestine, trachea, kidney, small intestine, stomach, and hematopoietic cells (4). There it regulates epithelial inflammation in response to inflammatory and infectious stimuli (5). MUC13 is aberrantly overexpressed in various cancer types including gastric (6), pancreatic (7), hepatic (8), colonic (9), renal (10), etc. The protein promotes tumorigenesis, metastasis, and induces resistance to chemotherapy via activating multiple signaling pathways, such as β-catenin signaling, Her2/EGFR signaling, and NF-kB signaling (8,9,11,12). The apparent molecular weight of MUC13 is varied from 70 to 90 kDa and 120 to 175 kDa in different cell lines, due to the different protein glycosylation status (13).
- van Putten, J.P.M. and Strijbis, K. (2017) J Innate Immun 9, 281-299.
- Kasprzak, A. and Adamek, A. (2019) Int J Mol Sci 20, 1288. doi: 10.3390/ijms20061288.
- Reynolds, I.S. et al. (2019) Cancer Metastasis Rev 38, 237-257.
- Williams, S.J. et al. (2001) J Biol Chem 276, 18327-36.
- Sheng, Y.H. et al. (2013) Mucosal Immunol 6, 557-68.
- Shimamura, T. et al. (2005) Cancer Sci 96, 265-73.
- Khan, S. et al. (2017) Oncogene 36, 491-500.
- Dai, Y. et al. (2018) Am J Pathol 188, 378-391.
- Sheng, Y.H. et al. (2019) Oncogene 38, 7294-7310.
- Sheng, Y. et al. (2017) Int J Cancer 140, 2351-2363.
- Tiemin, P. et al. (2020) J Hepatol 72, 761-773.
- Sheng, Y.H. et al. (2017) Oncogene 36, 700-713.
- Maher, D.M. et al. (2011) Mol Cancer Res 9, 531-537.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IHC-P: Immunohistochemistry (Paraffin) IF-IC: Immunofluorescence (Immunocytochemistry)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.